Table 3.
The NMA presents the impact of each intervention for disease-free survival
| Placebo | 1.03 (0.92,1.15) | 1.02 (0.93,1.12) | 1.04 (0.80,1.34) | 1.08 (0.80,1.45) | 1.03 (0.83,1.28) | 1.10 (0.97,1.25) | 1.20 (1.01,1.43) | 1.01 (0.83,1.23) | 1.06 (0.81,1.40) |
| 1.03 (0.92,1.15) | sunitinib | NA | NA | NA | NA | NA | NA | NA | NA |
| 1.02 (0.93,1.12) | 0.99 (0.86,1.15) | sorafenib | NA | NA | NA | NA | NA | NA | NA |
| 1.04 (0.80,1.34) | 1.01 (0.76,1.33) | 1.02 (0.78,1.33) | nivolumab + ipilimumab | NA | NA | NA | NA | NA | NA |
| 1.08 (0.80,1.45) | 1.05 (0.77,1.44) | 1.06 (0.78,1.44) | 1.04 (0.71,1.54) | IL2 + IFN + 5FU | NA | NA | NA | NA | NA |
| 1.03 (0.83,1.28) | 1.00 (0.79,1.28) | 1.01 (0.80,1.28) | 1.00 (0.71,1.39) | 0.96 (0.66,1.38) | atezolizumab | NA | NA | NA | NA |
| 1.10 (0.97,1.25) | 1.07 (0.91,1.27) | 1.08 (0.92,1.26) | 1.06 (0.80,1.41) | 1.02 (0.74,1.40) | 1.07 (0.83,1.37) | pazopanib | NA | NA | NA |
| 1.20 (1.01,1.43) | 1.17 (0.95,1.44) | 1.18 (0.97,1.44) | 1.16 (0.85,1.58) | 1.12 (0.79,1.57) | 1.17 (0.88,1.54) | 1.09 (0.88,1.35) | pembrolizumab | NA | NA |
| 1.01 (0.83,1.23) | 0.99 (0.79,1.24) | 0.99 (0.80,1.23) | 0.98 (0.71,1.35) | 0.94 (0.66,1.34) | 0.98 (0.73,1.31) | 0.92 (0.73,1.16) | 0.84 (0.65,1.09) | girentuximab | NA |
| 1.06 (0.81,1.40) | 1.03 (0.77,1.39) | 1.04 (0.78,1.39) | 1.02 (0.70,1.49) | 0.98 (0.66,1.47) | 1.03 (0.73,1.46) | 0.97 (0.71,1.30) | 0.88 (0.64,1.22) | 1.05 (0.75,1.47) | axitinib |